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1. INTRODUCTION {#cam42161-sec-0005}
===============

Upper tract urothelial carcinoma (UTUC) is a relatively rare but potentially fatal disease, which occurs in the pyelocaliceal cavities or ureter. It accounts for 5%‐10% of urothelial carcinomas.[1](#cam42161-bib-0001){ref-type="ref"} Although the radical nephroureterectomy (RNU) with bladder cuff excision has been considered as the standard treatment for the patients with UTUCs, the prognosis remains poor with a potential of intravesical recurrence and distant metastasis.[2](#cam42161-bib-0002){ref-type="ref"} Despite the use of adjuvant chemotherapy, the overall survival (OS) of the patients has not been improved because of the complications.[3](#cam42161-bib-0003){ref-type="ref"}, [4](#cam42161-bib-0004){ref-type="ref"} Therefore, the identification of the prognostic factors is needed to improve therapies.

Till now, many preoperative and postoperative prognostic factors of UTUC have been indicated,[5](#cam42161-bib-0005){ref-type="ref"}, [6](#cam42161-bib-0006){ref-type="ref"} such as lymphovascular invasion (LVI), tumor stage, tumor grade, tumor size, and lymph node invasion,[7](#cam42161-bib-0007){ref-type="ref"}, [8](#cam42161-bib-0008){ref-type="ref"} which can be used to predict prognosis and adapt the treatment for the patients of UTUC. However, there are limited data about preoperative prognostic factor in UTUC. Recently, amounting evidence has suggested that patients\' nutritional and immunologic conditions could influence the postoperative outcomes of malignant tumors, like breast cancer,[9](#cam42161-bib-0009){ref-type="ref"} nonsmall cell lung cancer,[10](#cam42161-bib-0010){ref-type="ref"} and colorectal cancer.[11](#cam42161-bib-0011){ref-type="ref"}

The prognostic nutritional index (PNI), which was calculated based on serum albumin levels and total lymphocyte count, was first reported by Buzby and colleagues in 1980.[12](#cam42161-bib-0012){ref-type="ref"} To date, many studies have proved that PNI is a significant indicator for prognosis in patients with several malignancies, but the prognostic value of PNI has been poorly investigated in UTUC. Therefore, our study was designed to identify the impact of PNI on the survival and pathologic outcomes of patients with UTUC after RNU.

2. PATIENTS AND METHODS {#cam42161-sec-0006}
=======================

2.1. Patient selection {#cam42161-sec-0007}
----------------------

A total of 806 patients with UTUC who underwent RNU from our institution were retrieved between January 2003 and December 2016. Patients with missing PNI data (n = 23), history of receiving preoperative chemotherapy or radiotherapy (n = 21), presence of inflammatory condition (n = 17), as well as those who were withdrawn within 3 months (n = 28) were excluded. Finally, 717 patients were included in the analyses. RNU was performed as standard procedure including the dissection of kidney with the entire part of ureter, and the bladder cuff resection. Lymphadenectomy was performed in the patients with enlarged lymph nodes which were indicated by preoperative radiology or intraoperative inspection.

2.2. Clinical and pathologic evaluation {#cam42161-sec-0008}
---------------------------------------

Clinical features including patients\' age, gender, surgical approach, smoking history, hydronephrosis, tumor size, and tumor side. Tumor stage was evaluated by the TNM classification system[13](#cam42161-bib-0013){ref-type="ref"} and tumor grade was assessed on the basis of the 1998 WHO consensus classification.[14](#cam42161-bib-0014){ref-type="ref"} LVI, multifocality, tumor architecture, and surgical margin status were reported by experienced urologic pathologists. The PNI data were extracted through the laboratory examination reports before surgery, which was calculated as 10 × serum albumin level (g/dL) + 0.005 × total lymphocyte count (per mm^3^).[15](#cam42161-bib-0015){ref-type="ref"}

2.3. Follow‐up {#cam42161-sec-0009}
--------------

Patients were assessed every 3 months for the first year and every 6 months for the second and third year after RNU. Then annually thereafter. Routine check‐ups included blood laboratory tests (blood routine examination, liver, and renal functions examination), medical history, cystoscopy, and imaging (chest/abdomen CT/MRI, carried out every year or if clinically indicated). Duration of follow‐up ranged from the date of operation to the latest follow‐up or death, which was defined as cancer related to the tumor or not.

2.4. Statistical analysis {#cam42161-sec-0010}
-------------------------

All the patients were divided into two groups: patients with PNI ≥46.91 and patients with PNI \<46.91. The cutoff value of PNI was defined as 46.91 according to the receiver operating characteristic (ROC) curves as well as Youden Index.[16](#cam42161-bib-0016){ref-type="ref"}, [17](#cam42161-bib-0017){ref-type="ref"} Student's *t* test and chi‐squared test were adapted to analyze the continuous and categorical variables, respectively. Kaplan‐Meier curves were used to calculate cancer‐specific survival (CSS), recurrence‐free survival (RFS), and OS. The differences were assessed by using the log‐rank test. Univariable and multivariable Cox regression models were conducted to evaluate the risk factors for CSS, RFS, and OS, and those with *P* \< 0.1 in the univariable model were accepted into the multivariable analyses. The multivariable Cox regression analysis was adjusted for tumor stage, tumor grade, tumor size, tumor architecture, surgical margin status, concomitant variant histology (CVH), lymph node status, LVI status, and PNI. Hazard ratios (HRs) were used to evaluate the strength of the variables with 95% CIs. The result of *P* \< 0.05 was defined as statistical significance. All the analyses were conducted using SPSS 22.0 (IBM SPSS, Chicago, IL).

3. RESULTS {#cam42161-sec-0011}
==========

3.1. Characteristics of included patients {#cam42161-sec-0012}
-----------------------------------------

The characteristics of patients with UTUC in our study are presented in Table [1](#cam42161-tbl-0001){ref-type="table"}. Of all the 717 patients included, 298 were in PNI \<46.91 group and 419 were in PNI ≥46.91 group. The cutoff of 46.91 was calculated by using the ROC curves (Figure 1). The median follow‐up duration was 50 months (interquartile range 28‐78 months). For the included patients, 408 (56.9%) were men and 309 (43.1%) were women. Four hundred and eighty‐four (67.5%) patients underwent open RNU and the remaining 233 (32.5%) patients underwent laparoscopic RNU. Among the patients, 205 (28.6%) had the tumor in the ureter, 385 (53.7%) had the tumor in the renal pelvis, and 127 (17.7%) had multifocal lesions. Pathological T stage was pTis/Ta/T1 in 221 cases (30.8%), pT2 in 145 (20.2%), pT3 in 248 (34.6%), and pT4 in 103 (14.4%). 71 (9.9%) patients were diagnosed with positive lymph nodes.

![ROC curve of PNI of RFS in patients with UTUC and the cutoff of PNI was 46.91, with a sensitivity of 63% and a specificity of 52.6%](CAM4-8-2971-g001){#cam42161-fig-0001}

###### 

Demographics and clinicopathological characteristics of patients with urinary tract urothelial carcinoma included in present study

  Characteristic                                  Total          PNI ＜46.91 (n = 298, 47.6%)   PNI ≥ 46.91 (n = 419, 52.4%)   *P*
  ----------------------------------------------- -------------- ------------------------------ ------------------------------ ---------
  Gender (male vs female)                         408/309        172/126                        236/183                        0.710
  Age (\>67 vs \<67 years)                        354/363        160/138                        194/225                        0.051
  Body mass index (≥25 vs \<25 kg/m^2^)           188/529        70/228                         118/301                        0.161
  Smoking history (yes vs no)                     204/513        89/209                         115/304                        0.479
  Tumor side (right vs left)                      350/367        154/144                        196/223                        0.196
  Surgical approach, *n* (%)                                                                                                   0.646
  Open RNU                                        484 (67.5)     204 (68.5)                     280 (66.8)                      
  Laparoscopic RNU                                233 (32.5)     94 (31.5)                      139 (33.2)                      
  Hydronephrosis (Yes vs No)                      447/270        177/121                        270/149                        0.170
  Tumor location, *n* (%)                                                                                                      0.013
  Pelvicalyceal                                   385 (53.7)     169 (56.7)                     216 (51.6)                      
  Ureteric                                        205 (28.6)     69 (23.2)                      136 (32.5)                      
  Both                                            127 (17.7)     60 (20.1)                      67 (16.0)                       
  Tumor grade (High vs Low)                       528/189        239/59                         289/130                        0.001
  Tumor stage, *n* (%)                                                                                                         \<0.001
  Tis, Ta, T1                                     221 (30.8)     74 (24.8)                      147 (35.1)                      
  T2                                              145 (20.2)     56 (18.8)                      89 (21.2)                       
  T3                                              248 (34.6)     107 (35.9)                     141 (33.7)                      
  T4                                              103 (14.4)     61 (20.5)                      42 (10.0)                       
  Lymph node status, *n* (%)                                                                                                   0.434
  pN0                                             90 (12.6)      41 (13.8)                      49 (11.7)                       
  pNx                                             556 (77.5)     224 (75.2)                     332 (79.2)                      
  pN+                                             71 (9.9)       33 (11.1)                      38 (9.1)                        
  LVI (positive vs negative)                      107/610        54/244                         53/366                         0.043
  Tumor size (＞3 vs ≤3 cm)                       488/229        207/91                         281/138                        0.497
  Surgical margin status (positive vs negative)   58/659         26/272                         32/387                         0.599
  Multifocality (present vs absent)               119/598        45/253                         74/345                         0.364
  Sessile vs papillary                            492/225        223/75                         269/150                        0.002
  CVH (with vs without)                           165/552        80/218                         85/334                         0.040
  Bladder cancer status, *n* (%)                                                                                               0.930
  No                                              616 (85.9)     255 (85.6)                     361 (86.2)                      
  Previous                                        22 (3.1)       10 (3.4)                       12 (2.9)                        
  Concomitant                                     79 (11.0)      33 (11.1)                      46 (11.0)                       
  Adjuvant therapy (yes vs no)                    291/426        117/181                        174/245                        0.543
  Serum albumin (g/L)                             39.74 ± 5.03   35.53 ± 4.36                   42.74 ± 2.85                   \<0.001
  Lymphocyte count (10^9^)                        1.73 ± 6.51    1.12 ± 0.43                    2.17 ± 8.49                    0.184

Abbreviations: RNU, radical nephroureterectomy; LVI, lymphovascular invasion; CVH, concomitant variant histology.
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3.2. Low PNI (\<46.91) independently predicted poor OS, RFS, and CSS {#cam42161-sec-0013}
--------------------------------------------------------------------

### 3.2.1. Low PNI and OS {#cam42161-sec-0014}

During the follow‐up, 260 patients (36.3%) died of all causes, and the 3‐year and 5‐year OS were 70.8% and 63.3% for the high PNI group, as well as 53.8% and 40.6% for the low PNI group, respectively. Kaplan‐Meier survival analysis suggested that patients with low PNI had worse OS compared to those with high PNI (log‐rank test, *P* \< 0.001) (Figure 2). Subsequently, our univariable analysis showed that patients with low PNI were statistically significantly correlated with worse OS (HR = 1.90, *P* \< 0.001; Table [2](#cam42161-tbl-0002){ref-type="table"}). Meanwhile, multivariable analysis revealed that low PNI was a significant indicator of worse OS (HR = 1.78, *P* \< 0.001; Table [3](#cam42161-tbl-0003){ref-type="table"}).

![Kaplan‐Meier curves for OS (A), RFS (B), and CSS (C) which were performed according to PNI value for UTUC patients after RNU](CAM4-8-2971-g002){#cam42161-fig-0002}

###### 

Univariable Cox regression analyses of survival outcomes in patients with UTUC

  Characteristic                                  Overall survival   Cancer‐specific survival   Recurrence‐free survival                                                           
  ----------------------------------------------- ------------------ -------------------------- -------------------------- ------- -------------- --------- ------- -------------- ---------
  Gender (male vs female)                         1.141              0.894‐1.457                0.290                      1.214   0.925‐1.593    0.163     1.167   0.929‐1.466    0.184
  Age (\>67 vs ≤67 years)                         1.020              0.800‐1.302                0.872                      0.928   0.707‐1.217    0.588     0.938   0.747‐1.177    0.581
  BMI (≥25 vs \< 25 kg/m^2^)                      0.953              0.726‐1.251                0.728                      0.878   0.645‐1.195    0.409     0.978   0.760‐1.259    0.864
  Smoking history (yes vs no)                     0.901              0.683‐1.188                0.458                      0.862   0.631‐1.177    0.350     0.884   0.682‐1.144    0.348
  Tumor side (right vs left)                      1.051              0.824‐1.341                0.687                      1.089   0.830‐1.428    0.538     1.063   0.847‐1.333    0.601
  Surgical approach (open vs laparoscopic)        0.724              0.541‐0.969                0.030                      0.677   0.490‐0.934    0.018     0.869   0.672‐1.124    0.285
  Hydronephrosis (yes vs no)                      1.342              1.035‐1.740                0.026                      1.249   0.938‐1.664    0.128     1.401   1.097‐1.788    0.007
  Tumor location, n (%)                                                                         0.712                                             0.537                            0.547
  Pelvicalyceal                                   1                  Reference                                             1       Reference                1       Reference       
  Ureteric                                        0.958              0.719‐1.277                0.771                      1.012   0.737‐1.390    0.941     0.955   0.731‐1.249    0.738
  Both                                            1.119              0.800‐1.565                0.510                      1.224   0.849‐1.763    0.279     1.154   0.846‐1.574    0.366
  Tumor grade (High vs Low)                       2.832              1.991‐4.028                \<0.001                    3.471   2.268‐5.313    \<0.001   2.276   1.679‐3.085    \<0.001
  Tumor stage, n (%)                                                                            \<0.001                                           \<0.001                          \<0.001
  Tis, Ta, T1                                     1                  Reference                                             1       Reference                1       Reference       
  T2 vs Tis, Ta, T1                               1.621              1.040‐2.529                0.033                      1.598   0.951‐2.686    0.077     1.499   1.011‐2.223    0.044
  T3 vs Tis, Ta, T1                               3.279              2.266‐4.744                \<0.001                    3.602   2.355‐5.511    \<0.001   2.836   2.041‐3.941    \<0.001
  T4 vs Tis, Ta, T1                               7.984              5.374‐11.861               \<0.001                    9.293   5.938‐14.544   \<0.001   6.974   4.857‐10.013   \<0.001
  Lymph node status, n (%)                                                                      \<0.001                                           \<0.001                          \<0.001
  pN0                                             1                  Reference                                             1       Reference                1       Reference       
  pNx vs pN0                                      1.524              0.995‐2.336                0.053                      1.516   0.928‐2.478    0.097     1.517   1.022‐2.252    0.039
  pN+ vs pN0                                      5.392              3.295‐8.823                \<0.001                    6.068   3.504‐10.509   \<0.001   5.496   3.467‐8.714    \<0.001
  LVI (positive vs negative)                      2.452              1.841‐3.265                \<0.001                    2.666   1.950‐3.645    \<0.001   2.177   1.652‐2.869    \<0.001
  Tumor size (\>3 vs ≤3 cm)                       1.988              1.494‐2.644                \<0.001                    2.029   1.473‐2.796    \<0.001   1.862   1.433‐2.420    \<0.001
  Surgical margin status (positive vs negative)   2.147              1.482‐3.111                \<0.001                    2.370   1.591‐3.532    \<0.001   1.898   1.321‐2.728    0.001
  Multifocality (present vs absent)               0.922              0.658‐1.291                0.635                      1.012   0.704‐1.456    0.947     0.947   0.694‐1.294    0.734
  Sessile vs papillary                            2.968              2.151‐4.095                \<0.001                    3.653   2.480‐5.380    \<0.001   2.536   1.906‐3.374    \<0.001
  CVH (with vs without)                           2.199              1.697‐2.850                \<0.001                    2.357   1.770‐3.138    \<0.001   2.019   1.578‐2.584    \<0.001
  Bladder cancer status, n (%)                                                                  0.136                                             0.203                            0.376
  No                                              1                  Reference                                             1       Reference                1       Reference       
  Previous                                        0.297              0.074‐1.198                0.088                      0.345   0.085‐1.391    0.134     0.903   0.425‐1.920    0.792
  Concomitant                                     1.198              0.835‐1.719                0.327                      1.205   0.809‐1.795    0.360     1.263   0.901‐1.770    0.176
  Adjuvant therapy (Yes vs No)                    0.858              0.671‐1.097                0.222                      0.920   0.701‐1.209    0.551     1.090   0.868‐1.369    0.456
  PNI (\<46.91 vs ≥46.91)                         1.895              1.485‐2.418                \<0.001                    2.014   1.534‐2.643    \<0.001   1.635   1.302‐2.054    \<0.001

Abbreviations: RNU, radical nephroureterectomy; LVI, lymphovascular invasion; CVH, concomitant variant histology.

John Wiley & Sons, Ltd

###### 

Multivariable Cox regression analysis of survival outcomes in patients with UTUC

  Characteristic                                  Overall survival   Cancer‐specific survival   Recurrence‐free survival                                                         
  ----------------------------------------------- ------------------ -------------------------- -------------------------- ------- ------------- --------- ------- ------------- ---------
  Tumor grade (high vs low)                       1.736              1.188‐2.537                0.004                      1.944   1.235‐3.061   0.004     1.483   1.066‐2.064   0.019
  Tumor stage, n (%)                                                                            \<0.001                                          0.001                           \<0.001
  Tis, Ta, T1                                     1                  Reference                                             1       Reference               1       Reference      
  T2 vs Tis, Ta, T1                               1.203              0.757‐1.914                0.434                      1.101   0.641‐1.893   0.727     1.168   0.774‐1.763   0.459
  T3 vs Tis, Ta, T1                               1.889              1.233‐2.895                0.003                      1.860   1.142‐3.028   0.013     1.834   1.256‐2.679   0.002
  T4 vs Tis, Ta, T1                               2.837              1.710‐4.705                \<0.001                    2.723   1.536‐4.828   0.001     3.008   1.892‐4.780   \<0.001
  Lymph node status, n (%)                                                                      \<0.001                                          \<0.001                         \<0.001
  pN0                                             1                  Reference                                             1       Reference               1       Reference      
  pNx vs pN0                                      2.005              1.297‐3.098                0.002                      1.995   1.212‐3.284   0.007     1.930   1.294‐2.880   0.001
  pN+ vs pN0                                      3.174              1.877‐5.367                \<0.001                    3.460   1.933‐6.193   \<0.001   3.348   2.043‐5.486   \<0.001
  LVI (positive vs negative)                      1.079              0.783‐1.487                0.643                      1.101   0.778‐1.560   0.586     0.961   0.702‐1.315   0.801
  Tumor size (\>3 vs ≤3cm)                        1.717              1.273‐2.318                \<0.001                    1.717   1.226‐2.404   0.002     1.603   1.220‐2.106   0.001
  Surgical margin status (positive vs negative)   1.126              0.762‐1.662                0.552                      1.191   0.785‐1.809   0.411     1.046   0.713‐1.533   0.819
  Sessile vs papillary                            1.520              1.043‐2.215                0.029                      1.737   1.110‐2.718   0.016     1.415   1.011‐1.979   0.043
  CVH (with vs without)                           1.392              1.060‐1.827                0.017                      1.435   1.064‐1.934   0.018     1.291   0.996‐1.674   0.054
  PNI (\<46.91 vs ≥46.91)                         1.777              1.383‐2.284                \<0.001                    1.850   1.399‐2.445   \<0.001   1.554   1.229‐1.964   \<0.001

Abbreviations: RNU, radical nephroureterectomy; LVI, lymphovascular invasion; CVH, concomitant variant histology.
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### 3.2.2. Low PNI and RFS {#cam42161-sec-0015}

The 3‐year and 5‐year RFS were 63.0% and 55.2% for the high PNI group, and 46.6% and 39.1% for the low PNI group, respectively. The Kaplan‐Meier curve proved that the rate of disease recurrence was higher in the low PNI group than that in the high PNI group (*P* \< 0.001) (Figure [2](#cam42161-fig-0002){ref-type="fig"}). Moreover, univariable Cox regression analysis suggested that low PNI was significantly associated with the higher rate of disease recurrence (HR = 1.64, *P* \< 0.001; Table [2](#cam42161-tbl-0002){ref-type="table"}). Low PNI was also indicated as a significant indicator of poor RFS through the multivariable Cox regression analysis (HR = 1.55, *P* \< 0.001; Table [3](#cam42161-tbl-0003){ref-type="table"}).

### 3.2.3. Low PNI and CSS {#cam42161-sec-0016}

A total of 209 patients (29.1%) died from cancer during follow‐up, and 3‐year and 5‐year CSS were 58.4% and 48.3% for the low PNI group and 75.5% and 68.1% for the high PNI group, respectively. Patients with low PNI had a significant worse CSS rate (*P* \< 0.001) compared to the patients with high PNI according to the Kaplan‐Meier survival curve (Figure [2](#cam42161-fig-0002){ref-type="fig"}). Univariable analysis revealed that low PNI was significantly correlated with unfavorable CSS (HR = 2.01, *P* \< 0.001). At the same time, multivariable analysis showed low PNI was a significant prognostic factor for poorer CSS (HR = 1.85, *P* \< 0.001; Table [2](#cam42161-tbl-0002){ref-type="table"}).

Furthermore, our analysis also suggested that high tumor grade, tumor stage of T3 or T4, lymph node invasion, CVH, tumor size ≥3 cm, and sessile carcinoma also correlated with poor OS, RFS, and CSS (all *P* \< 0.05; Table [3](#cam42161-tbl-0003){ref-type="table"}).

4. DISCUSSION {#cam42161-sec-0017}
=============

In our study, we found that PNI was a significant predictor for worse pathologic and oncologic outcomes in patients with UTUC. Comparing with the patients with high PNI, those with low PNI had decreased OS, RFS, and CSS. In the multivariable analysis, we found that PNI was an independent prognostic factor for OS, RFS, and CSS in UTUC.

PNI was first performed as a predictive indicator by Buzby and colleagues,[12](#cam42161-bib-0012){ref-type="ref"} who reported a complex formula as: PNI = 158‐0.78 × triceps skinfold (mm) -- 16.6 × albumin (g/100 mL) -- 5.8 × cutaneous delayed hypersensitivity -- 0.20 × transferrin (mg/100 mL). In contrast, Onodera and coworkers[15](#cam42161-bib-0015){ref-type="ref"} calculated the PNI based on the total lymphocyte count and the serum albumin levels, which were more easily assessable. In our study, we used the latter method, and the ROC curve analysis suggested the cutoff value of PNI was 46.91. When the PNI was 46.91, the specificity and sensitivity for the 5‐year CSS were 52.6% and 63.0%, respectively.

PNI, a combination of serum albumin and lymphocyte count, has been reported as a useful predictor in several malignancies (eg. Lung cancer,[10](#cam42161-bib-0010){ref-type="ref"} breast cancer,[9](#cam42161-bib-0009){ref-type="ref"} colorectal cancer,[11](#cam42161-bib-0011){ref-type="ref"} and renal cell carcinoma [18](#cam42161-bib-0018){ref-type="ref"}). To date, we found that only a single study, which was conducted by Huang et al in 2017,[19](#cam42161-bib-0019){ref-type="ref"} had reported the prognostic value of PNI in UTUC. Four hundred and twenty‐five patients were included in their study and the results showed that PNI was a useful independent predictor for patients with UTUCs, which was consistent with our findings. In our analysis, we had a larger sample size and included more indicators, which was helpful for risk prediction in UTUCs.

Recently, a growing body of literature revealed that cancer‐related malnutrition had a negative influence on treatment outcomes, prognosis, and survival.[20](#cam42161-bib-0020){ref-type="ref"}, [21](#cam42161-bib-0021){ref-type="ref"} It is widely accepted that malnutrition takes a very important place in immune system, but malnutrition influences the immune functions which are fundamental to prevent infection or cancer through the cell‐mediated mechanism or other immune pathways.[22](#cam42161-bib-0022){ref-type="ref"}, [23](#cam42161-bib-0023){ref-type="ref"} Many studies have showed that preoperative malnutrition has a negative effect on the survival outcomes in patients with urologic carcinomas,[20](#cam42161-bib-0020){ref-type="ref"}, [24](#cam42161-bib-0024){ref-type="ref"} but few studies are performed to investigate the influence in UTUCs.[25](#cam42161-bib-0025){ref-type="ref"}, [26](#cam42161-bib-0026){ref-type="ref"}

The PNI could be calculated by serum albumin level and lymphocyte count, both of which were routinely assessed and can be easily obtained by urologists before surgery. It is well accepted that lymphocyte plays an important role in cell‐mediated immunity in several cancers. As a result, the lymphocyte count could be a predictor of the survival. Serum albumin is also a simple marker for estimating the protein levels, which is usually used as a predictor of nutritional status. Gupta and colleagues[27](#cam42161-bib-0027){ref-type="ref"} investigated the connection between the serum albumin level and the treatment outcomes of patients with various cancers. Therefore, serum albumin levels are useful prognostic factors in malignant tumors.

In our study, the cutoff of PNI was calculated by the ROC curve analysis, and the mean value of PNI was lower than that in patients with renal cell carcinoma (RCC)[18](#cam42161-bib-0018){ref-type="ref"} but higher than that in patients with esophageal carcinoma.[11](#cam42161-bib-0011){ref-type="ref"} This finding shows that malnutrition is more common in gastrointestinal malignancy compared with UTUCs, and bad appetite and gastric obstruction may be the main reasons. As for the malnutrition in RCC is less common than that in UTUC, the age with the peak incidence in patients with UTUC is older than those with RCC might account for this.

In addition to PNI, the tumor stage, grade, size, architecture, variant histology, and lymph node invasion are proved as independent predictors in UTUC. Many of them have been recommended as prognostic factors by European Association of Urology guidelines and used for risk stratification except PNI.[1](#cam42161-bib-0001){ref-type="ref"} It may be because there are scarce studies concerning the prognostic value of PNI in UTUC. Even though the pathologic indicators, such as tumor stage, sessile carcinoma, positive lymph node, and CVH have higher HR than PNI, they just could be obtained via invasive therapy or after surgery. Conversely, we can calculate the PNI easily and rapidly from the preoperative laboratory examination results. Meanwhile, the blood test is cheaper than image examination, which could be used to estimate the tumor size. In addition, if the PNI could be recommended as a useful clinical reference, preoperative therapy such as neoadjuvant chemotherapy could be adopted to improve the outcomes. Therefore, we conducted this study to identify the independent predictors in UTUC, trying to provide more evidence for the risk stratification in UTUC.

A few limitations of our study should be noticed. First, it was a retrospective single center study, so the selection and information bias might not be avoided. Besides, some specific inflammatory indicator like cytokines and CRP were not routinely tested for the patients with UTUC, so we could not estimate their prognostic value. Furthermore, more high‐quality studies with long follow‐up time are still needed to provide more evidences for the prognostic value of PNI in patients with UTUC.

5. CONCLUSION {#cam42161-sec-0018}
=============

In conclusion, patients with low PNI had worse OS, CSS, and RFS. PNI is an independent predictor of oncologic outcomes in patients with localized UTUC after RNU. Therefore, we recommended that PNI could be incorporated in the traditional prognostic model, as an important predictor for the patients with UTUC.
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